A Research Triangle Park pharmaceutical startup that on Thursday received $143,000 in a loan from the North Carolina Biotechnology Center is eyeing a much larger capital infusion. Jenken Biosciences, which has more drugs in its pipeline than it does full-time employees, is trying to raise between $9 million and $10 million in series A financing, said CEO Barry Buzogany.
